Found 19 clinical trials
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PLATCOV)
(no treatment): Newly available and repurposed potential antiviral drugs; B: Positive control: monoclonal antibodies initially but subsequently any therapeutic that is shown to
- 0 views
- 07 Oct, 2022
- 2 locations
Effect of Direct-acting Antiviral Drugs on Erectile Function
Effect of direct-acting antiviral drugs on erectile function
- 38 views
- 26 Feb, 2022
- 1 location
Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with hematopoietic stem cell transplantation.
- 0 views
- 26 Jul, 2021
- 1 location
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
samples will be collected as well. People with KICS that requires treatment may get new experimental treatments. These treatments may include antiviral drugs and chemotherapy drugs, depending
- 81 views
- 24 Oct, 2022
- 1 location
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
-19. Additionally further trials and clinical observations have not found a significant benefit of other antiviral drugs. Although the results of several studies are still pending, there is still a
- 0 views
- 10 Jul, 2022
- 2 locations
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
accompanied by an extremely high mortality rate and therefore the development of new treatment approaches is required. Despite the available antiviral drugs, a considerable number of patients are facing an
- 47 views
- 24 Feb, 2022
- 8 locations
Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn …
- 43 views
- 07 Oct, 2022
- 7 locations
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
We will conduct a phase 4, multicenter, open-label trial at 7 academic centers in Taiwan. Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir disoproxil fumarate [TDF]) for at least 2 years, and fulfil the following nucleos(t)ide analogs discontinuation criteria. After nucleos(t)ide analogs discontinuation, patients had a clinical …
- 0 views
- 12 Aug, 2021
- 7 locations
Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001
The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to elicit a robust protective IgG immune response in vaccine naive subjects in subjects who failed to demonstrate seroconversion after treatment with a licensed hepatitis B vaccine and in patients chronically infected with HBV.
- 12 views
- 12 Feb, 2022
- 2 locations
Antiviral Therapy for Patients With Chronic Hepatitis B Infection
The study aims to demonstrate that antiviral therapy for patients with immune tolerance of CHB. On the basis of the original antiviral therapy of entecavir, further clarify the safety and effectiveness of entecavir combined with tenofovir amibufenamide.The investigators plan to enroll about 328 hepatitis B patients,. who are in the …
- 0 views
- 08 Jun, 2022
- 1 location
- 1
- 2